Anti-Suicide Drugs Market

Global Anti-Suicide Drugs Market Size, Share and Trends Analysis Report, By Drug Class (Anti-Depressant and Anti-Anxiety Drugs, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antibiotic Analog, Anti-Psychotic Drugs, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Forecast (2021-2027)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2026086 | Category : Pharmaceuticals | Delivery Format: /

The global anti-suicide drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Anti-suicide drugs are anti-psychotic and anti-depressant drugs. They are prescribed to prevent patients from suicidal thoughts and attempts. Additionally, they are also given to cure the underlying conditions which lead a person to have suicidal tendencies. Furthermore, depression is one of the major reasons that lead to suicide. The major factor driving the demand for anti-suicide drugs is the increasing cases of suicide across the globe. 

According to the American Foundation for Suicide Prevention, in 2019 suicide is the 10th leading cause of mortality in the US. Additionally, there was a mortality rate of 47,511 people from suicide in the US. Furthermore, there were 1.38 million suicide attempts with an age-adjusted suicide rate of 13.93 per 100,000 individuals in 2019. Hence, the increasing incidence of suicide is driving the demand for anti-suicide drugs which in turn is driving the growth of the market. 

Some major players in the market include Pfizer, Inc., Johnson & Johnson Services, Inc., and GlaxoSmithKline plc, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in August 2020, Janssen Pharmaceuticals, Inc. announced the approval of Spravato from the US Food and Drug Administration (FDA). Spravato is a nasal spray used for the treatment of suicidal patients with major depression.

Market Coverage

The market number available for – 2020-2027

Base year- 2020

Forecast period- 2021-2027

Segment Covered- 

o By Drug Class

o By Distribution Channel

Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape- Pfizer, Inc., Johnson & Johnson Services, Inc., and GlaxoSmithKline plc, among others.

Key questions addressed by the report

What is the market growth rate?

Which segment and region dominate the market in the base year?

Which segment and region will project the fastest growth in the market?

How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?

How players are addressing challenges to sustain growth?

Where is the investment opportunity?

Global Anti-Suicide Drugs Market Report by Segment

By Drug Class

Anti-Depressant and Anti-Anxiety Drugs

N-Methyl-D-Aspartate (NMDA) Receptor Antagonists

Antibiotic Analog

Anti-Psychotic Drugs

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Anti-Suicide Drugs Market Report by Region

North America

United States

Canada

Europe

UK

Germany

Italy

Spain

France

Rest of Europe 

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific 

Rest of the World

Latin America 

Middle East & Africa